Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a partnership with Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. The collaboration aims to strengthen the development of a “Chinese model” for the diagnosis and treatment of rare diseases, with a focus on hemophilia B, complemented by insurance coverage.
Focus on Hemophilia B and Patient Management
The partnership will initially concentrate on hemophilia B, a chronic rare disease that requires long-term treatment. While no financial or specific deal details have been disclosed, the two firms will collaborate on patient management for chronic rare diseases, innovative payment methods, and other initiatives designed to benefit patients with hemophilia B.
Human Coagulation Factor IX and Its Applications
Human coagulation factor IX, recommended by guidelines for the preventive treatment of patients with hemophilia B, is extensively used across various medical departments, including hematology, pediatric hematology, orthopedics, and rehabilitation. Yuanda Shuyang Pharmaceutical’s human coagulation factor IX received marketing approval in China on February 14, 2023. The product has been launched with a patient welfare care program, established in partnership between Yuanda Shuyang and MediTrust Health, to support hemophilia B patients.-Fineline Info & Tech
